These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 26544577)

  • 1. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
    Wilkin TJ; Lalama CM; McKinnon J; Gandhi RT; Lin N; Landay A; Ribaudo H; Fox L; Currier JS; Mellors JW; Gulick R; Tenorio AR
    J Infect Dis; 2012 Aug; 206(4):534-42. PubMed ID: 22740718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
    AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.
    Rusconi S; Vitiello P; Adorni F; Colella E; Focà E; Capetti A; Meraviglia P; Abeli C; Bonora S; D'Annunzio M; Di Biagio A; Di Pietro M; Butini L; Orofino G; Colafigli M; d'Ettorre G; Francisci D; Parruti G; Soria A; Buonomini AR; Tommasi C; Mosti S; Bai F; Di Nardo Stuppino S; Morosi M; Montano M; Tau P; Merlini E; Marchetti G
    PLoS One; 2013; 8(11):e80157. PubMed ID: 24244635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
    Hunt PW; Shulman NS; Hayes TL; Dahl V; Somsouk M; Funderburg NT; McLaughlin B; Landay AL; Adeyemi O; Gilman LE; Clagett B; Rodriguez B; Martin JN; Schacker TW; Shacklett BL; Palmer S; Lederman MM; Deeks SG
    Blood; 2013 Jun; 121(23):4635-46. PubMed ID: 23589670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
    Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
    PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
    Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.
    Stepanyuk O; Chiang TS; Dever LL; Paez SL; Smith SM; Perez G; Eng RH
    AIDS; 2009 Sep; 23(14):1911-3. PubMed ID: 19584703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
    Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
    J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.
    Gutiérrez C; Hernández-Novoa B; Vallejo A; Serrano-Villar S; Abad-Fernández M; Madrid N; Díaz L; Moreno A; Dronda F; Zamora J; Muñoz-Fernández MA; Moreno S
    AIDS; 2013 Aug; 27(13):2081-8. PubMed ID: 24384589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
    Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
    J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
    Minami R; Takahama S; Kaku Y; Yamamoto M
    J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.
    Beliakova-Bethell N; Jain S; Woelk CH; Witt MD; Sun X; Lada SM; Spina CA; Goicoechea M; Rought SE; Haubrich R; Dubé MP
    Antiviral Res; 2014 Jul; 107():42-9. PubMed ID: 24769244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
    Bocket L; Peytavin G; Alidjinou EK; Ajana F; Choisy P; Lê M; Charpentier C; Descamps D; Yazdanpanah Y; Katlama C; Simon A; Calvez V; Marcelin AG; Soulie C
    J Antimicrob Chemother; 2016 Sep; 71(9):2651-3. PubMed ID: 27234463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
    Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R
    J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.
    Negredo E; Massanella M; Puertas MC; Buzón MJ; Puig J; Pérez-Alvárez N; Pérez-Santiago J; Bonjoch A; Moltó J; Jou A; Echeverría P; Llibre JM; Martínez-Picado J; Clotet B; Blanco J
    J Antimicrob Chemother; 2013 Oct; 68(10):2358-62. PubMed ID: 23677919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
    Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
    Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.